# Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

> **NCT00369174** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Oral Leukoplakia

## Interventions

- **DRUG:** rosiglitazone maleate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00369174
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369174, "Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00369174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*